Latest News in Cancer
Stay updated with the most recent articles and resources.
Main Topics
China to open borders for patients travelling for medical treatment
China to open its borders for the first time since COVID pandemic outbreak. Borders will open for all types of visa. Check how to obtain...
March month is colorectal cancer awareness month
March month if observed as colorectal cancer awareness month. Colorectal cancer is second most deadly cancer on this planet and early diagnosis is required for...
Peter MacCallum Cancer Centre and Cartherics will collaborate on ovarian cancer CAR-T cell therapy
Peter MacCallum Cancer Centre (Peter Mac) and Cartherics Pty Ltd have entered into a collaborative development programme to develop CAR T Cell therapy for ovarian...
New drug for primary bone cancer in children
As per the report published in the Journal of Bone Oncology, researchers from the University of East Anglia’s Norwich Medical School demonstrated, that the drug...
KITE AND ARCELLX CLOSE AGREEMENT TO CO-DEVELOP AND CO-COMMERCIALIZE LATE-STAGE CLINICAL CART-DDBCMA IN MULTIPLE MYELOMA
SANTA MONICA, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’...
Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI®(ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
JANUARY 27, 2023—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today...
Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China
SOMERSET, N.J.—JANUARY 2, 2023— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases,...
JW Therapeutics Announces Initiation of Clinical Study of JWATM214 in Patients with Advanced Hepatocellular Carcinoma
SHANGHAI, CHINA, February 28, 2023 – JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced...
JW Therapeutics Presents Latest Clinical Data on Carteyva® in Follicular Lymphoma and Mantle Cell Lymphoma at the 64th ASH Annual Meeting
SHANGHAI, CHINA, December 12, 2022 An independent and creative biotechnology company called JW Therapeutics (HKEX: 2126) focuses on developing, manufacturing, and selling cell immunotherapy products....
JW Therapeutics Announces That Its Cell Immunotherapy Drugs Have Successfully Benefited 300 Patients
SHANGHAI, CHINA, November 9, 2022 – JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherapy products, announced...
JW Therapeutics and 2seventy bio Announce Strategic Partnership to Accelerate the Research and Development of T-cell-based Immunotherapies
SHANGHAI, CHINA and CAMBRIDGE, MASSACHUSETTS, US, October 27, 2022 – JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing...
JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in Patients with Relapsed or Refractory Follicular Lymphoma
SHANGHAI, CHINA, October 10, 2022 – JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherapy products, announced...
Need help? Our team is ready to assist you.
We wish a speedy recovery for your loved ones.